<p>Nemysis Limited is pleased to announce the successful acquisition of TFarma SRL ("TFarma") by its wholly-owned subsidiary, Enteralia Bioscience SRL ("Enteralia").</p>

Nemysis is pleased to announce the further strengthening of its IP portfolio in relation to its unique and innovative nanoparticulate oral iron supplement, IHAT (Iron Hydroxide Adipate Tartrate), for the safe treatment of iron deficiency and iron deficiency anaemia.

Nemysis Ltd and Bruno Farmaceutici SpA are pleased to announce they have signed a non-exclusive sales and marketing agreement for IHAT (Iron Hydroxide Adipate Tartrate), Nemysis' innovative oral iron supplementation product.

Nemysis has entered into Heads of Terms for two nonexclusive sales and marketing agreements with two potential partners for the sale and marketing of its IHAT product within the Italian market.

Nemysis Ltd Announces Grant of First Chinese Patent for IHAT, the Novel Iron Nanoparticulate Supplement for Iron Deficiency (ID) and Iron Deficiency With Anemia (IDA).

Nemysis Limited, the Dublin based pharmaceutical and healthcare Company, focused on Iron Deficiency/Anemia and Gluten Sensitivity, today announced that the South Africa Patent and Trademark Office on issued S.A. Patent No.ZA201802192, with claims of Methods for Producing Carboxylate Ligand Modified Ferric Iron Hydroxide Colloids and Related Compositions and Uses, directed to the use of oral iron supplementation.

Nemysis Limited, the Dublin-based pharmaceutical and healthcare Company focused on iron deficiency/anemia and gluten sensitivity has announced that it has completed a €2.65M capital raise.